Leveraging bioorthogonal chemistry- and split-luciferase assay technologies, we have devised a new assay for the live-cell detection of RNA–protein interactions, RNA interaction with Protein-mediated Complementation Assay or RiPCA.
Dysregulation of the networking of RNA-binding proteins (RBPs) and RNAs drives many human diseases, including cancers, and the targeting of RNA–protein interactions (RPIs) has emerged as an exciting area of RNA-targeted drug discovery.